RCT of everolimus and exercise for postmenopausal bone loss shows no reported effect sizes.
This 24-week randomized controlled trial enrolled 136 postmenopausal women (aged 45-60) assigned to control, exercise training, everolimus (5 mg weekly), or combined treatment. The primary outcome was percentage change in bone formation marker P1NP at week 24, with secondary outcomes including bone resorption marker CTX, bone mineral density, bone structure, muscle function, and postural balance. The study does not report the effect sizes or results for any outcome.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 7, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 136
- Duration
- 6 months
- Population
- Healthy postmenopausal women aged 45-60 years with T-score >-3 and no history of hip, Colles' or symptomatic vertebral fractures within the last 6 months
- Primary outcome
- Percentage change in bone formation marker P1NP (Procollagen Type 1 propeptide) between baseline and week 24
- Effect size
- —
- Significance
- Not reported
- Journal
- Odense University Hospital
- Published
- Apr 7, 2026
Sources
Primary source
- Odense University Hospital ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.